Higashi T, Sano H, Saishoji T, Ikeda K, Jinnouchi Y, Kanzaki T, Morisaki N, Rauvala H, Shichiri M, Horiuchi S
Department of Biochemistry, Kumamoto University School of Medicine, Japan.
Diabetes. 1997 Mar;46(3):463-72. doi: 10.2337/diab.46.3.463.
Long-term incubation of proteins with glucose leads to advanced glycation end products (AGEs) with fluorescence and a brown color. We recently demonstrated immunologically the intracellular AGE accumulation in smooth muscle cell (SMC)-derived foam cells in advanced atherosclerotic lesions. To understand the mechanism of AGE accumulation in these foam cells, we have now characterized the interaction of AGE proteins with rabbit-cultured arterial SMCs. In experiments at 4 degrees C, 125I-labeled AGE-bovine serum albumin (AGE-BSA) showed a dose-dependent saturable binding to SMCs with an apparent dissociation constant (Kd) of 4.0 microg/ml. In experiments at 37 degrees C, AGE-BSA underwent receptor-mediated endocytosis and subsequent lysosomal degradation. The endocytic uptake of 125I-AGE-BSA was effectively inhibited by unlabeled AGE proteins such as AGE-BSA and AGE-hemoglobin, but not by acetylated LDL and oxidized LDL, well-known ligands for the macrophage scavenger receptor (MSR). Moreover, the binding of 125I-AGE-BSA to SMCs was affected neither by amphoterin, a ligand for one type of the AGE receptor, named RAGE, nor by 2-(2-furoyl)-4(5)-(2-furanyl)-1H-imidazole-hexanoic acid-BSA, a ligand for the other AGE receptors, p60 and p90. This indicates that the endocytic uptake of AGE proteins by SMCs is mediated by an AGE receptor distinct from MSR, RAGE, p60, and p90. To examine the functional role of this AGE receptor, the migratory effects of AGE-BSA on these SMCs were tested. Incubation with 1-50 microg/ml of AGE-BSA for 14 h resulted in significant dose-dependent cell migration. The AGE-BSA-induced SMC migration was chemotactic in nature and was significantly inhibited (approximately 80%) by an antibody against transforming growth factor-beta (TGF-beta), and the amount of TGF-beta secreted into the culture medium from SMC by AGE-BSA was sevenfold higher than that of control, indicating that TGF-beta is involved in the AGE-induced SMC chemotaxis. These data suggest that AGE may play a role in SMC migration in advanced atherosclerotic lesions.
蛋白质与葡萄糖长期孵育会产生具有荧光和棕色的晚期糖基化终产物(AGEs)。我们最近通过免疫学方法证明了晚期动脉粥样硬化病变中平滑肌细胞(SMC)衍生的泡沫细胞内AGE的积累。为了解这些泡沫细胞中AGE积累的机制,我们现在对AGE蛋白与兔培养的动脉SMC的相互作用进行了表征。在4℃的实验中,125I标记的AGE-牛血清白蛋白(AGE-BSA)显示出与SMC的剂量依赖性饱和结合,表观解离常数(Kd)为4.0μg/ml。在37℃的实验中,AGE-BSA经历了受体介导的内吞作用和随后的溶酶体降解。未标记的AGE蛋白如AGE-BSA和AGE-血红蛋白可有效抑制125I-AGE-BSA的内吞摄取,但乙酰化LDL和氧化LDL(巨噬细胞清道夫受体(MSR)的已知配体)则不能。此外,125I-AGE-BSA与SMC的结合既不受两性调节蛋白(一种名为RAGE的AGE受体的配体)的影响,也不受2-(2-呋喃甲酰基)-4(5)-(2-呋喃基)-1H-咪唑己酸-BSA(其他AGE受体p60和p90的配体)的影响。这表明SMC对AGE蛋白的内吞摄取是由一种不同于MSR、RAGE、p60和p90的AGE受体介导的。为了研究这种AGE受体的功能作用,我们测试了AGE-BSA对这些SMC的迁移作用。用1-50μg/ml的AGE-BSA孵育14小时导致显著的剂量依赖性细胞迁移。AGE-BSA诱导的SMC迁移本质上是趋化性的,并且被抗转化生长因子-β(TGF-β)抗体显著抑制(约80%),并且AGE-BSA从SMC分泌到培养基中的TGF-β量比对照高7倍,表明TGF-β参与了AGE诱导的SMC趋化作用。这些数据表明AGE可能在晚期动脉粥样硬化病变中的SMC迁移中起作用。